Neos Therapeutics, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2006, the company has made significant strides in developing innovative treatments for attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. Neos is particularly known for its unique extended-release formulations, which enhance patient compliance and therapeutic outcomes. With a focus on delivering high-quality, effective medications, Neos Therapeutics has established a strong market position, recognised for its commitment to research and development. The company’s flagship products, including Adzenys XR-ODT and Cotempla XR-ODT, stand out for their distinctive delivery systems, offering patients convenient and effective treatment options. Through its dedication to advancing ADHD therapies, Neos continues to make a meaningful impact in the lives of patients and healthcare providers alike.
We don't have data for Neos Therapeutics, Inc., but we can show you information about their parent organization instead.
View parent company